China’s Breakthrough Obesity Drug Mazdutide Achieves Record Weight Loss in Global Study
A landmark Phase 3 clinical study of mazdutide, the world’s first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, has been…
A landmark Phase 3 clinical study of mazdutide, the world’s first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, has been…
Obesity isn’t just about weight—it’s a complex medical condition linked to serious health risks like diabetes, heart disease, and cancer. But…
The global obesity drug market is experiencing significant growth, with projections exceeding $150 billion annually in the coming decade. This…
Key Findings at a Glance The Study: How Weight-Loss Drugs Stack Up Against Surgery A landmark Israeli study (presented at the European Congress…
Obesity is one of the most misunderstood health crises of our time. Below, we tackle the most pressing questions—backed by…
Artificial Intelligence (AI) is transforming healthcare—and it’s now playing a critical role in tackling one of the world’s most pressing…
A Scientific Mystery Solved In a breakthrough that defies conventional logic, researchers have discovered that two completely opposite drug strategies—stimulating and blocking the same…